May 2018: A Message from the President
It’s May, and spring is finally here (though this weather could have come a little sooner). Winters in the Midwest are often about staying inside — hibernating a bit, if you will — to recuperate for the better weather to come, which then fills this time of year with more energy and excitement. I, for one, am certainly excited about everything ASBMT has planned for the coming year.
May 2018: Policy Perspective
When I am crunched for time, I make lists. As the Centers for Medicare and Medicaid Services (CMS) Inpatient Prospective Payment System (IPPS) FY2019 Proposed Rule came out on April 24 and is chock-full of issues that impact our field, I am most definitely crunched for time — meaning that this month, we have a “listicle” update for you from the policy team at ASBMT. Here are the primary items to know about the proposed rule and what sections and specifics relate to HCT and CAR-T therapies.
Meet the ASBMT Team
A new monthly series, ASBMT's "Meet the Team" section will introduce you to the people who run the day-to-day operations of ASBMT. If you have any questions or need to reach out to someone on the team, please don't hesitate to reach out; we love hearing from and helping members!
4th International Workshop on Biology, Prevention and Treatment of Relapse after Hematopoietic Stem Cell Transplantation
Register today for the 4th International Workshop on Biology, Prevention and Treatment of Relapse after HSCT. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation (HSCT). The planned objectives of the workshop are designed to present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational and clinical research specifically related to this field.
CAR-T Library Slides Now Available to ASBMT Members
Immune effector cell therapy is a new, rapidly growing, and changing field. Educational initiatives are lagging as the field continues to evolve. The CAR-T (chimeric antigen receptor T-ell therapy) Working Group is an ongoing educational initiative to create a comprehensive resource library of CAR-T therapy developed by working group members.